Physician profile
Sean C Su
NPI 1346211414
$15,938.76
in general payments reported to CMS, 2019-2025
23 companies · $2,958 in 2025
The $2,958 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,901 · 2020: $1,004 · 2021: $2,281 · 2022: $2,615 · 2023: $3,018 · 2024: $2,162 · 2025: $2,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,050 · Education: $87.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,050.24 |
| Education | $87.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,750.03 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,999.10 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,890.30 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,721.36 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,388.04 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,030.22 | 2019-2025 | Ingrezza |
| Abbvie INC. | $947.49 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $678.21 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $663.17 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $659.68 | 2019-2022 | |
| Lundbeck LLC | $602.86 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $576.62 | 2019-2025 | Trintellix |
| Allergan, INC. | $254.10 | 2019-2020 | |
| Indivior INC. | $248.74 | 2019-2024 | Perseris |
| Merck Sharp & Dohme LLC | $234.59 | 2022-2023 | Belsomra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $97.21 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $50.76 | 2021-2022 | |
| Tempus Ai, INC | $42.88 | 2024 | |
| Ironshore Pharmaceuticals INC. | $29.30 | 2019 | |
| Shire North American Group INC | $27.27 | 2019 | |
| Braeburn INC. | $18.75 | 2024 | Brixadi |
| Idorsia Pharmaceuticals US INC | $16.67 | 2023 | Quviviq |
| Neuronetics, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.